α-二氢麦角隐亭治疗帕金森病的有效性和安全性
Efficacy and safety of α-dihydroergocryptine in the treatment of early and advanced Parkinson's disease
作者：彭蓉,周东,赖晓辉,袁光固
Author：
收稿日期： 年卷（期）页码：2004,(04):-313-315
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：帕金森病;α-二氢麦角隐亭;治疗;安全性
Key words：
基金项目：
中文摘要
目的 评价α -二氢麦角隐亭单药治疗及其与左旋多巴联合治疗帕金森病的有效性和安全性。方法 采用前瞻性和开放性的方法 ,用联合帕金森病评分 (UPDRS)对两组患者治疗前、后的运动能力进行评定。结果 在UPDRSⅢ评分中 ,α -二氢麦角隐亭治疗 90d时A组下降了 33% (P
参考文献
[1] BattistinL ,BardinPG ,Ferro-MoilongF ,etal.Alpha-dihydroer gocryptineinParkinson’sdisease:amulticentrerandomizeddoubleblindparallelgroupstudy[J].ActaNeurolScand,1999,99:36
[2] HughesAH ,DanielSE ,KilfordL ,etal.Accuracyofclinicaldiagno sisofidiopathicParkinson’sdisease:aclinico-pathologicalstudyof100cases[J].JNeurolNeurosurgPsychiatry,1992,55:181
[3] HoehnMM ,YahrMD .Parkinsonism:onset,progression,andmortality[J].Nerrology,1967,17:427
[4] BergamascoB ,FrattolaL ,MuratorioA ,etal.Alpha-dihydroer gocryptineinthetreatmentofdenovoparkinsonianpatients:resultsofamulticentre,randomized,double-blind,placebo-controlledstudy[J].ActaNeurolScand,2000101(6):372
[5] RoncaF ,GuazzelliM ,SalvadoriP ,etal.Pharmacokineticandmetabolismstudyinhealthyvolunteersafteradministrationofsingleo raldoseof3H -dihydroergocryptinemesylatd[J].AmJTher,1996,3:553
【关闭】
